Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Deleted in breast cancer-1 (DBC-1) in the interface between metabolism, aging and cancer
Chini, Eduardo N. , Chini, Claudia C.S. , Nin, Verónica , Escande, Carlos , Chini, Eduardo Nunes

Bioscience Reports | July 23, 2013 | Volume: 33 | Issue: 4 | Pages: No page available

10.1042/bsr20130062 | PMID 23841676 Get It

DBC1 (deleted in breast cancer-1) is a nuclear protein that regulates cellular metabolism. Since alteration in cellular metabolism have been proposed to be the emerging ‘hallmark’ of cancer, it is possible that DBC1 may be implicated in the regulation of cancer cell energy metabolism. However, at this point any role of DBC1 in cancer is only speculative. In this review, we will discuss the new developments in DBC1 research, its molecular structure, regulatory roles and implication in metabolism, aging and cancer.
Protein kinase D-mediated phosphorylation at Ser99 regulates localization of p21-activated kinase 4
Bastea, Ligia I. , Döppler, Heike, Durand, Nisha , Spratley, Samantha J., Störz, Peter , Pearce, Sarah E. , Bastea, Ligia

Biochemical Journal | July 23, 2013 | Volume: 455 | Issue: 2 | Pages: 251-260

10.1042/bj20130281 | PMID 23841590 Get It

PAKs (p21-activated kinases) are effectors of RhoGTPases. PAK4 contributes to regulation of cofilin at the leading edge of migrating cells through activation of LIMK (Lin-11/Isl-1/Mec-3 kinase). PAK4 activity is regulated by an autoinhibitory domain that is released upon RhoGTPase binding as well as phosphorylation at Ser474 in the activation loop of the kinase domain. In the present study, we add another level of complexity to PAK4 regulation by showing that phosphorylation at Ser99 is required for its targeting to the leading edge. This phosphorylation is mediated by PKD1 (protein kinase D1). Phosphorylation of PAK4 at Ser99 also mediates binding to 14-3-3 protein, and is required for the formation of a PAK4–LIMK–PKD1 complex that regulates cofilin activity and directed cell migration.
Executive Summary: A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a
Baron, Ellen Jo , Weinstein, Melvin P., Richter, Sandra S. , Gilligan, Peter H., Thomson, Richard B., Bourbeau, Paul, Kehl, Sue C., Robinson-Dunn, Barbara, Schwartzman, Joseph D., Chapin, Kimberle, Snyder, James W. , Forbes, Betty A., Patel, Robin , Rosenblatt, Jon E., Pritt, Bobbi S. , Miller, J. Michael , Carroll, Karen C. , Dunne, William Michael , Patel, Robin , Pritt, Bobbi S

Clinical Infectious Diseases | July 23, 2013 | Volume: 57 | Issue: 4 | Pages: 485-488

10.1093/cid/cit441 | PMID 23881727 Get It

Abstract The critical role of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working relationship between the physician and the microbiologists who provide enormous value to the health care team. This document, developed by both laboratory and clinical experts, provides information on which tests are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. Sections are divided into anatomic systems, including Bloodstream Infections and Infections of the Cardiovascular System, Central Nervous System Infections, Ocular Infections, Soft Tissue Infections of the Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract infections, Infections of the Gastrointestinal Tract, Intraabdominal Infections, Bone and Joint Infections, Urinary Tract Infections, Genital Infections, and Skin and Soft Tissue Infections; or into etiologic agent groups, including Tickborne Infections, Viral Syndromes, and Blood and Tissue Parasite Infections. Each section contains introductory concepts, a summary of key points, and detailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or have prolonged turnaround times. There is redundancy among the tables and sections, as many agents and assay choices overlap. The document is intended to serve as a reference to guide physicians in choosing tests that will aid them to diagnose infectious diseases in their patients.
Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer
Carlson, Aaron , Maurer, Matthew J. , Goergen, Krista M., Kalli, Kimberly R., Erskine, Courtney L. , Behrens, Marshall D., Knutson, Keith L. , Block, Matthew S. , Carlson, Aaron M, Knutson, Keith L. , Maurer, Matthew

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2013 | Volume: 22 | Issue: 10 | Pages: 1730-1735

10.1158/1055-9965.epi-12-1368 | PMID 23878295 Get It

Abstract Background: Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related death in females and leading gynecologic cause of cancer-related death. Despite the identification of a number of serum biomarkers, methods to identify early-stage disease and predict prognosis remain scarce. We have evaluated two biologically connected serum biomarkers, serum leukocyte protease inhibitor (SLPI) and progranulin (PGRN). Methods: Two-hundred frozen plasma samples were acquired from the Mayo Clinic Biospecimen Repository for Ovarian Cancer Research. Samples were obtained from 50 patients with benign conditions, 50 with American Joint Committee on Cancer (AJCC) stage I and II EOC, and 100 with AJCC stage III and IV EOC. Samples were obtained before surgical resection of a mass and were analyzed for absolute levels of SLPI and PGRN using ELISA assays. Receiver-operator characteristic curves were generated for SLPI and PGRN. Median follow-up was 48 months. Results: Absolute levels of SLPI were significantly elevated in patients with EOC compared with benign disease and predicted the presence of EOC (AUC of 0.812; P = 0.04); SLPI remained elevated in the subset of patients with normal CA-125. PGRN levels were not significantly increased in patients with early-stage or late-stage EOC as a whole, but an increase in PGRN levels was associated with decreased overall survival in advanced EOC. Conclusions: SLPI levels are elevated in EOC, and SLPI shows promise as a diagnostic biomarker for patients with both elevated and normal CA-125 levels. An increase in PGRN is associated with decreased overall survival. Impact: SLPI is elevated in EOC and warrants investigation in a screening study in women at risk for EOC. Cancer Epidemiol Biomarkers Prev; 22(10); 1730–5. ©2013 AACR.
Iatrogenic Brachial Plexus Injuries Associated With Open Subpectoral Biceps Tenodesis
Rhee, Peter C. , Spinner, Robert J. , Shin, Alexander Y. , Bishop, Allen T. , Shin, Alexander Y

The American Journal of Sports Medicine | July 22, 2013 | Volume: 41 | Issue: 9 | Pages: 2048-2053

10.1177/0363546513495646 | PMID 23876520 Get It

Clinical Reasoning: A 39-year-old woman with progressive proximal weakness
Quinn, Colin , Karam, Chafic

Neurology | July 22, 2013 | Volume: 81 | Issue: 4 | Pages: 400-402

10.1212/wnl.0b013e31829c5eb0 | PMID 23877797 Get It

In transcatheter aortic valve replacement: To balloon or not to balloon, that is the question
Al-Omari, Malik A., Levy, Michael

Catheterization and Cardiovascular Interventions | July 22, 2013 | Volume: 82 | Issue: 2 | Pages: 298-299

10.1002/ccd.25079 | PMID 23878037 Get It

Faculty Opinions recommendation of Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 22, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718025942.793480357 Get It

Faculty Opinions recommendation of Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 22, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718002950.793480361 Get It

The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle‐aged men and differs from time trends in systemic diffuse large B‐cell non‐Hodgkin's lymphoma
Decker, Paul A. , Tieu, Christina, Cerhan, James R. , O'Neill, Brian Patrick, O’Neill, Brian Patrick , Decker, Paul A. , Cerhan, James R

American Journal of Hematology | July 22, 2013 | Volume: 88 | Issue: 12 | Pages: 997-1000

10.1002/ajh.23551 | PMID 23873804 Get It

There has been an overall decline in the United States incidence of Primary CNS Lymphoma (PCNSL) from 1998 to 2008. This study's intent was to characterize the cohorts contributing to it. First, calculated the PCNSL incidence rates from nine Surveillance, Epidemiology, and End Results (SEER) registries for time period 1973 to 2008. Second, examined the time trends overall and by age and gender. Third, used 1992–2008 SEER data from the same registries to obtain overall trends for diffuse large B‐cell lymphoma (DLBCL). Last, rates were age‐adjusted to the 2000 US standard population and reported per 100,000 person‐years. Rates continued to increase in women at all ages and men aged 65 and older. In men aged 20–39 and 40–64 years incidence rates peaked in 1995 and then declined dramatically, stabilizing after 1998. The trends in the incidence of PCNSL over this time frame were significantly different from DLBCL for ages 20–39 (P < 0.001) and 40–64 (P < 0.001) years but were not different for the 65 years and older age group (P = 0.99). The overall PCNSL incidence rate declined since 1995 and was driven primarily by the changing incidence in young and middle‐aged men. The rate has continued to increase in men aged 65 years and older and in women. The trends in incidence in the younger age groups over this time period did not parallel those observed for DLBCL. Am. J. Hematol. 88:997–1000, 2013. © 2013 Wiley Periodicals, Inc.